Related Experiment Videos
Anti-HIV therapy: Current and future directions.
Lokesh Agrawal1, Xihua Lu, Qingwen Jin
1Department of Microbiology & Immunology and the Walther Cancer Institute, Indiana University School of Medicine, Medical Science Building, 635 Barnhill Drive, Rm#420, Indianapolis, IN 46202, USA.
Current Pharmaceutical Design
|June 22, 2006
Summary
New HIV therapeutics are crucial due to drug resistance and side effects. Novel drugs targeting viral entry, integrase, and regulatory proteins, alongside immunomodulators, offer promising new treatment avenues beyond current therapies.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Current combination therapies for HIV/AIDS have limitations including viral escape, drug resistance, and patient non-compliance.
- The need for novel therapeutic strategies and an effective HIV vaccine is paramount to overcome existing treatment challenges.
Purpose of the Study:
- To review emerging therapeutic approaches for Human Immunodeficiency Virus (HIV) infection.
- To highlight novel drug classes and strategies that offer alternative mechanisms of action.
Main Methods:
- Review of recently identified drug classes targeting HIV entry.
- Discussion of agents targeting viral fusion proteins (gp41) and coreceptors (CCR5, CXCR4).
- Exploration of novel targets including HIV integrase and regulatory gene products, as well as immunomodulators (IL-12, IL-2).
Main Results:
- Two new classes of drugs inhibiting HIV membrane fusion have been identified.
- FDA-approved agents like enfuvirtide (T-20) and T-1249 block gp41 function.
- Agents targeting CCR5 and CXCR4 are in clinical trials, with others targeting integrase and regulatory proteins under development.
Conclusions:
- Novel therapeutic strategies are essential to address limitations of current HIV treatments.
- Inhibitors of viral entry, integrase, and regulatory proteins represent promising avenues for future HIV therapy.
- Development of new drugs and an HIV vaccine is critical for advancing HIV/AIDS management.